| 摘要 |
The invention relates to the use of a substance or polypeptide according to the formula X1-X2-X3-Thr-X4-Lys-X5-Arg-X6 (SEQ ID NO:22), wherein X1 is Ala or Gly, X2 is Tyr or Phe, X3, X4 and X5 are independently selected from the group consisting of Met, Ile, Leu and Val; and X6 is selected from the group consisting of Asp, Gln and Glu, optionally at least one of X1, X2, X3, X4, X5 and X6 is independently substituted with a non-natural or unusual amino acid and/or the peptide is cyclized and/or the peptide is stabilized and/or the amino terminal amino acid residue is acylated and/or the carboxy terminal amino acid residue is amidated, and peptidomimetics modelled on the basis of the above formula for the preparation of a pharmaceutical composition for the reduction of TNF.alpha. production and/or for the prophylaxis or treatment of pancreatitis and/or for the prophylaxis or treatment of viral infections such as acquired immunodeficiency syndrom (AIDS) or cutaneous HPV-infection. In particular, the invention relates to analogues of peptides of the above formula wherein at least one of X1, X2, X3, X4, X5 and X6 is independently substituted with a non-natural or unusual amino acid and/or the peptide is cyclized and/or the peptide is stabilized and/or the amino terminal amino acid residue is acylated and/or the carboxy terminal amino acid residue is amidated, and peptidomimetics moldelled on the basis of the above formula.
|
